VIPDOMET 12.5/850; 12.5 mg alogliptin (as benzoate) / 850 mg metformin hydrochloride film-coated tablets blister pack

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

metformin hydrochloride, Quantity: 850 mg; alogliptin benzoate, Quantity: 17 mg (Equivalent: alogliptin, Qty 12.5 mg)

Disponible depuis:

Takeda Pharmaceuticals Australia Pty Ltd

DCI (Dénomination commune internationale):

Alogliptin benzoate,Metformin hydrochloride

forme pharmaceutique:

Tablet, film coated

Composition:

Excipient Ingredients: titanium dioxide; crospovidone; povidone; microcrystalline cellulose; mannitol; purified talc; magnesium stearate; iron oxide yellow; hypromellose

Mode d'administration:

Oral

Unités en paquet:

20, 196, 28, 56, 200, 98, 14, 60, 120, 112, 10, 180

Type d'ordonnance:

(S4) Prescription Only Medicine

indications thérapeutiques:

VIPDOMET is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,VIPDOMET can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

Descriptif du produit:

Visual Identification: Light yellow, oblong, biconvex, film-coated tablet with 12.5/850 debossed on one side and 322M debossed on the other side; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Statut de autorisation:

Licence status A

Date de l'autorisation:

2013-10-22